- Home
- DAWN vs ETWO Comparison
DAWN vs ETWO Comparison
Compare DAWN & ETWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- ETWO
- Stock Information
- Founded
- DAWN 2018
- ETWO 2000
- Country
- DAWN United States
- ETWO United States
- Employees
- DAWN N/A
- ETWO N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- ETWO EDP Services
- Sector
- DAWN Health Care
- ETWO Technology
- Exchange
- DAWN Nasdaq
- ETWO Nasdaq
- Market Cap
- DAWN 658.9M
- ETWO 663.4M
- IPO Year
- DAWN 2021
- ETWO N/A
- Fundamental
- Price
- DAWN $6.71
- ETWO $3.30
- Analyst Decision
- DAWN Strong Buy
- ETWO Sell
- Analyst Count
- DAWN 6
- ETWO 4
- Target Price
- DAWN $30.17
- ETWO $2.78
- AVG Volume (30 Days)
- DAWN 1.3M
- ETWO 3.0M
- Earning Date
- DAWN 08-05-2025
- ETWO 07-10-2025
- Dividend Yield
- DAWN N/A
- ETWO N/A
- EPS Growth
- DAWN N/A
- ETWO N/A
- EPS
- DAWN N/A
- ETWO N/A
- Revenue
- DAWN $161,922,000.00
- ETWO $609,135,000.00
- Revenue This Year
- DAWN $17.98
- ETWO $1.84
- Revenue Next Year
- DAWN $49.50
- ETWO $2.32
- P/E Ratio
- DAWN N/A
- ETWO N/A
- Revenue Growth
- DAWN N/A
- ETWO N/A
- 52 Week Low
- DAWN $6.08
- ETWO $1.75
- 52 Week High
- DAWN $16.76
- ETWO $4.82
- Technical
- Relative Strength Index (RSI)
- DAWN 47.98
- ETWO 68.08
- Support Level
- DAWN $6.32
- ETWO $3.21
- Resistance Level
- DAWN $7.18
- ETWO $3.24
- Average True Range (ATR)
- DAWN 0.29
- ETWO 0.01
- MACD
- DAWN 0.01
- ETWO -0.01
- Stochastic Oscillator
- DAWN 36.11
- ETWO 83.33
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About ETWO E2open Parent Holdings Inc.Class A
E2open Parent Holdings Inc is an end-to-end and cloud-based supply chain management SaaS platform. The company's software combines networks, data, and applications to provide a deeply embedded, mission-critical platform that allows customers to optimize the supply chain across channel shaping, business planning, logistics, trade, manufacturing, and supply management. The Group has one reportable segment consisting of cloud-based, end-to-end SCM software. Geographically, the company operates in the Americas, Europe, and Asia Pacific, out of which the majority is from the Americas.